Navigation Links
Mesenchymal stem cell transplantation may heal a mother's childbirth injury

Putnam Valley, NY. (Sept. 17 2013) Vaginal delivery presents the possibility of injury for mothers that can lead to "stress urinary incontinence" (SUI), a condition affecting from four to 35 percent of women who have had babies via vaginal delivery. Many current treatments, such as physiotherapy and surgery, are not very effective.

Seeking better methods to alleviate SUI, researchers carried out a study in which female laboratory rats modeled with simulated childbirth injuries received injections of mesenchymal stem cells (MSCs; multipotent cells found in connective tissues that can differentiate into a variety of cell types including: bone, cartilage and fat cells) to see if the cells would home to and help to repair the damaged pelvic organs.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at

"Stem cell-based therapy has recently gained attention as a promising treatment for SUI," said study co-author Dr. Margot S. Damaser of the Cleveland Clinic's Department of Biomedical Engineering. "Stem cell therapies may be more feasible and less invasive than current therapies."

The current study extended the results of the researcher's previous studies by demonstrating that the transplanted MSCs homed to the animals' spleens. This suggested that the transplanted cells could have a beneficial impact when they released trophic factors, agents that stimulate differentiation and survival of cells and then engrafted into the smooth muscle of the urethra and vagina, as demonstrated previously in prior studies.

"Our results suggest a potential therapy for postpartum SUI," said Dr. Damaser.

The group of female rats that received simulated childbirth injury (vaginal distension) and MSCs showed homing of the MSCs to the urethra and vagina, facilitating the recovery of continence.

The researchers noted that other kinds of stem cells from different sources have been used in other studies aimed at treating SUI via stem cell transplantation. Autologous (self-donated) muscle-derived stem cells have demonstrated therapeutic potential for SUI in animal models and in clinical trials. Adipose (fat)-derived stem cells have also been used to improve urethral function after simulated childbirth injury in rats.

This study used MSCs, cells which are believed to be "immune-privileged," with no rejection issues. The advantage in this, said the researchers, is that MSCs may have potential as an "off-the-shelf" therapy.

"Since rat MSCs were used in this study, the results can only be applied to rat models of injury-treated rats," explained Dr. Damaser. "Human adult stem cells need to be investigated in future studies to see if these findings also apply to humans."

The researchers suggested that their work also has potential to develop into a therapy for older women with SUI at a time "remote from delivery."

"This study provides evidence that mesenchymal stem cell transplantation could favorably impact a side effect of delivery and aging by releasing factors that can influence the urethra and vagina to treat stress urinary incontinence" said Dr Amit N. Patel, director of cardiovascular regenerative medicine at the University of Utah and section editor for Cell Transplantation. "Further studies are required to confirm that this animal study translates to humans."


Contact: Robert Miranda
Cell Transplantation Center of Excellence for Aging and Brain Repair

Related biology news :

1. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
2. 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes
3. Some factors that impact islet transplantation explored in Cell Transplantation papers
4. Some factors that impact islet transplantation explored in Cell Transplantation papers
5. Stem cell transplantation into mouse cochlea may impact future hearing loss therapies
6. New studies show spinal cord injury and ALS respond to cell transplantation
7. Studies in Cell Transplantation investigate oxygens impact as a factor in transplantation
8. Neurons made from stem cells drive brain activity after transplantation in laboratory model
9. Cell Transplantation reports islet cell advancement increases impact on transplantation
10. Cell Transplantation study investigates fate and function of cells transplanted to the CNS
11. Impact of stem cell transplantation location in brain a crucial factor for cell survival
Post Your Comments:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: